Anavex (AVXL) Narx-foyda multiplikatori
Dori vositalarini sintez qilishni avtomatlashtirish qarz yukiga ta'sir qiluvchi xarajatlarni talab qiladi va joriy narx-foyda ko'rsatkichi ushbu xarajatlarni vizuallashtiradi. -6.50 indikatori grafikdagi metrikaning miqdorini belgilaydi. Optimallashtirish kelajakdagi patent monopoliyasi va Alzheimer bemorlari uchun dorilarning FDA tomonidan tasdiqlanishi orqali yuqori daromadlilik bilan amalga oshirilishi mumkin, bu esa Anavex Life Sciences (AVXL) kompaniyasiga ulkan miqyosdagi effektni taqdim etadi.
Anavex Life Sciences Corp. (AVXL) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi tafsilotlari:
- emitentning balans qiymati statistikasi:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning kapitalga nisbati Anavex Life Sciences|AVXL - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi Anavex Life Sciences Corp.|AVXL - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Anavex Corp|AVXL - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzi Anavex Life Sciences|Oraliq qoplama koeffitsiyenti anavex.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
AVXL - Sof foyda|Forvard foyda Anavex Life Sciences|AVXL - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Anavex Life Sciences|AVXL - Narx-foyda va o‘sish multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Anavex Corp|AVXL - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Anavex Life Sciences|AVXL - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi anavex.com|AVXL - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Anavex Life Sciences
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning umumiy tahlili:Anavex - AVXL
P/E koeffitsiyenti biznesning bozor qiymatini uning sof foydasi bilan nisbatda o'lchaydi, bu esa investorga aktiv uchun haddan tashqari ko'p to'lov qilinganligini yoki marja qisqarishi xavfini baholash imkonini beradi. Anavex Life Sciences (AVXL) kompaniyasining P/E koeffitsiyenti dinamikasini tahlil qilishda biotexnologiya sohasining o'ziga xos jihatlarini hisobga olish muhimdir: markaziy nerv tizimi kasalliklarini davolash uchun yuqori R&D xarajatlari koeffitsiyentni vaqtincha buzishi mumkin, bu esa haqiqiy investitsiya jozibadorligini aniqlashda ehtiyotkorlikni talab qiladi.
Raqobatdosh kompaniyalar tahlili
Narxning foydaga nisbati BIIB|P/E multiplikatori NBIX|Regencell (RGC) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati axsome.com AXSM|P/E multiplikatori ACADIA Pharmaceuticals ACAD|XENE - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Narxning foydaga nisbati|CPRX (Catalyst Pharmaceuticals) - Narxning foydaga nisbati|DNLI (denalitherapeutics.com) - P/E multiplikatori|Narx-foyda multiplikatori HRMY (Harmony Biosciences Holdings, Inc.)|P/E multiplikatori BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Kapitalizatsiyaning sof foydaga nisbati|CBLL: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PRTA (prothena.com)|Alector, Inc. (ALEC) - Narxning foydaga nisbati|Narx-foyda multiplikatori ANNX|Narxning foydaga nisbati Omeros Corp.|Neurogene Therapeutics (NGNE) - Biznesning o‘zini qoplash muddati|P/E multiplikatori ACIU|VYGR (Voyager Therapeutics) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori NMRA (neumoratx.com)|SCLX: Narx-foyda multiplikatori|TVGN - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Alpha Cognition Inc.|CGTX: P/E multiplikatori|inhibikase.com (IKT) - P/E multiplikatori|Narxning foydaga nisbati Cassava Sciences Inc|ASRT - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati Coya (COYA)|P/E multiplikatori VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E multiplikatori|Biznesning o‘zini qoplash muddati alteritytherapeutics.com ATHE|CLNN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati PepGen Corp (PEPG)|Narxning foydaga nisbati Jupiter Neurosciences, Inc.|RLMD: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ANVS|Narx-foyda koeffitsiyenti Grace Tx GRCE|Narxning foydaga nisbati Firefly Neuroscience, Inc AIFF|KLTO: Narx-foyda multiplikatori|NRSN - Narxning foydaga nisbati|RVPH: Narxning foydaga nisbati|MTVA (MetaVia Inc.) - Narx-foyda koeffitsiyenti|NeurAxis Inc. (NRXS) - P/E multiplikatori|Narxning foydaga nisbati Helius Medical|Passage Bio, Inc. - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti NEUP (Neuphoria)|NERV - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ATHA (athira.com)|P/E multiplikatori Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E multiplikatori|CYCN - P/E multiplikatori|PTIX (Protagenic Therapeutics, Inc.) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Pasithea (KTTA)|Narxning foydaga nisbati Cortigent|Kapitalizatsiyaning foydaga nisbati Avenue Therapeutics Inc. ATXI|Narxning foydaga nisbati brainstorm-cell.com (BCLI)|Narx-foyda koeffitsiyenti Cara Therapeutics, Inc CARA|P/E multiplikatori CHRO (chromocell.com)|Kompaniya qiymatining sof foydaga nisbati ELYM|Intra-Cellular Therapies Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Longboard Pharmaceuticals Inc|Marinus (MRNS) - Narxning foydaga nisbati|NKGN - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati NeuroBo Pharmaceuticals|SAGE: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SNPX|Trevena Inc. - Narx-foyda multiplikatori|Narxning foydaga nisbati Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Narxning foydaga nisbati|Cerevel Therapeutics - P/E multiplikatori
